Skip to main content Accessibility help
×
Home
  • Print publication year: 2011
  • Online publication date: December 2011

3 - Mechanisms of neuronal injury and cerebral protection

from Section 1 - Applied clinical physiology and pharmacology

Related content

Powered by UNSILO

Further reading

Bosnjak, Z. J. and Sarantopoulos, C. D. (2009). Channels of preconditioning: potassium drain that protects the brain. Anesthesiology 110, 961–3.
Bracken, M. B., Shepard, M. J., Holford, T. R. et al. (1997). Administration of methylprednisolone for 24 and 48 hours or tirilazat mesylate for 48 hours in the treatment of acute spinal-cord injury. Results from the third national acute spinal cord injury randomized controlled trial. JAMA 277, 1597–1604.
Bullock, M. and Povlishock, J. (2007). Guidelines for the management of severe traumatic brain injury. J Neurotrauma 24 (Suppl. 1), S1–95.
Chamorro, A. and Hallenbeck, J. (2006). The harms and benefits of inflammatory and immune responses in vascular disease. Stroke 37, 291–3.
Della Morte, D., Abete, P., Gallucci, F. et al. (2008). Transient ischemic attack before nonlacunar ischemic stroke in the elderly. J Stroke Cerebrovasc Dis 17, 257–62.
Dirnagl, U., Klehmet, J., Braun, J. S. et al. (2007). Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke 38, 770–3.
Dirnagl, U., Becker, K. and Meisel, A. (2009). Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. Lancet Neurol 8, 398–412.
Emsley, H. C., Smith, C. J., Georgiou, R. F. et al. (2005). A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 76, 1366–72.
Enlimomab Acute Stroke Trial Investigators (2001). Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 57, 1428–34.
Fabricius, M., Fuhr, S., Bahtia, R. et al. (2006). Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. Brain 129, 778–90.
Gidday, J. M. (2006). Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 7, 437–48.
Ginsberg, M. (2008). Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 55, 363–89.
Green, A. R. and Ashwood, T. (2005). Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. Curr Drug Targets CNS Neurol Disord 4, 109–18.
Haley, E. C. Jr, Thompson, J. L., Levin, B. et al. (2005). Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies. Stroke 36, 1006–10.
Harms, H., Prass, K., Meisel, C. et al. (2008). Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS ONE 3, e2158.
Johnston, S. C. (2004). Ischemic preconditioning from transient ischemic attacks? Data from the Northern California TIA Study. Stroke 35, 2680–2.
Kawaguchi, M., Furuya, H. and Patel, P. M. (2005). Neuroprotective effects of anesthetic agents. J Anesth 19, 150–6.
Krams, M., Lees, K. R., Hacke, W. et al. (2003). Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose–response study of UK-279276 in acute ischemic stroke. Stroke 34, 2543–8.
Lampl, Y., Boaz, M., Gilad, R. et al. (2007). Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69, 1404–10.
Lewis, S. C., Warlow, C. P., Bodenham, A. R. et al. (2008). General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial. Lancet 372, 2132–42.
Low, C., Zheng, F., Lyuboslavsky, P. and Traynelis, S. (2000). Molecular determinants of coordinated proton and zinc inhibition of N-methyl-d-apartate NR1/NR2 receptors. Proc Natl Acad Sci U S A 97, 11,062–7.
Lucas, S. M., Rothwell, N. J. and Gibson, R. M. (2006). The role of inflammation in CNS injury and disease. Br J Pharmacol 147, S232–40.
Macleod, M. R., Fisher, M., O’Collins, V. et al. (2009). Reprint: Good laboratory practice: preventing introduction of bias at the bench. J Cereb Blood Flow Metab 29, 221–3.
Mergenthaler, P., Dirnagl, U. and Meisel, A. (2004). Pathophysiology of stroke: lessons from animal models. Metab Brain Disease 19, 151–67.
Mohr, J., Orgogozo, J., Harrison, M. et al. (1994). Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovascular Diseases 4, 197–203.
Muir, K. W., Lees, K. R., Ford, I. and Davis, S. (2004). Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 363, 439–45.
Nakanishi, N., Tu, S., Shin, Y. et al. (2009). Neuroprotection by the NR3A subunit of the NMDA receptor. J Neurosci 29, 5260–5.
Potts, M. B., Koh, S. E., Whetstone, W. D. et al. (2006). Traumatic injury to the immature brain: inflammation, oxidative injury, and iron-mediated damage as potential therapeutic targets. NeuroRx 3, 143–53.
Prass, K., Braun, J. S., Dirnagl, U., Meisel, C. and Meisel, A. (2006). Stroke propagates bacterial aspiration to pneumonia in a model of cerebral ischemia. Stroke 37, 2607–12.
Siesjo, B., Bengtsson, F., Grampp, W. and Theander, S. (1989). Calcium, excitotoxins, and neuronal death in the brain. Ann N Y Acad Sci 568, 234–51.
Siren, A. L., Fasshauer, T., Bartels, C. and Ehrenreich, H. (2009). Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 6, 108–27.
Slemmer, J. E., Zhu, C., Landshamer, S. et al. (2008). Causal role of apoptosis-inducing factor for neuronal cell death following traumatic brain injury. Am J Pathol 173, 1795–805.
Starkov, A., Chinopoulos, C. and Fiskum, G. (2004). Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. Cell Calcium 36, 257–64.
Verweij, B. H., Muizelaar, J. P., Vinas, F. et al. (2000). Impaired cerebral mitochondrial function after traumatic brain injury in humans. J Neurosurg 93, 815–20.
Wegener, S., Gottschalk, B., Jovanovic, V. et al. (2004). Transient ischemic attacks before ischemic stroke: preconditioning the human brain? A multicenter magnetic resonance imaging study. Stroke 35, 616–21.
Wong, G. K., Poon, W. S., Chan, M. T. et al. 2010). Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke 41, 921–6.
Xiang, Z., Yuan, M., Hassen, G., Gampel, M. and Bergold, P. (2004). Lactate induced excitotoxicity in hippocampal slice cultures. Exp Neurol 186, 70–7.
Zhang, Z., Artelt, M., Burnet, M., Trautmann, K. and Schluesener, H. J. (2006). Early infiltration of CD8+ macrophages/microglia to lesions of rat traumatic brain injury. Neuroscience 141, 637–44.
Zhang, Z. G., Chopp, M., Tang, W. X., Jiang, N. and Zhang, R. L. (1995). Postischemic treatment (2–4 h) with anti-CD11b and anti-CD18 monoclonal antibodies are neuroprotective after transient (2 h) focal cerebral ischemia in the rat. Brain Res 698, 79–85.
Zhao, H. (2009). Ischemic postconditioning as a novel avenue to protect against brain injury after stroke. J Cereb Blood Flow Metab 29, 873–85.